Background: Sintilimab, a novel full-humanized IgG 4 anti-PD-1 monoclonal antibody, showed its potent anti-tumor efficacy in preclinical models. Hence, we evaluated the efficacy and safety of sintilimab in combination with gemcitabine and cisplatin in treatment naïve advanced squamous cell non-small cell lung cancer (scNSCLC) patients in a multi-center phase Ib study in China (NCT02937116). Method: Histologically or cytologically confirmed locally advanced (stage IIIB), relapsed and metastatic (stage IV) scNSCLC patients who had not received any standard systemic treatment were recruited and received Sintilimab 200mg Q3W in combination with gemcitabine and cisplatin regimen, until disease progression or intolerant toxicity. Adverse events (AEs) were graded by NCI CTCAE v4.03. Tumor response was assessed by RECIST 1.1 and irRECIST every 9 weeks. Results: By August 1 st 2018, a total of 20 patients (19 males), with a median age of 65 years were enrolled in this study and received at least one dose of sintilimab. Nine patients were stage Ⅳ at baseline. The median treatment duration was 21.1 (0.1w34.3) weeks and median treatment cycle was 7.5 (1w12). Overall response rate was 64.7%, based on data of 17 patients who have received at least one radiological assessment. The other 6 patients had best response of stable disease. Both median progression free survival and duration of response were not reached. Treatment emergent adverse event (TEAE) occurred in all patients, 70% of which were grade 3 or over, but none of them were related to sintilimab. The most common treatment-related AEs were rash (3 patients) and fever (2 patients). Three patients experienced immunerelated AE, including 1 rash, 1 hyperthyroidism and 1 interstitial pneumonitis. Serious AE (SAEs) occurred in 8 patients, including 3 platelet count decrease, 1 neutrophil count decrease, 1 dysphagia, 1 pneumonia, 1 hydronephrosis and 1 interstitial pneumonitis. All SAEs were recovered or resolved after management except dysphagia. No AE leading to death occurred in this study. Conclusion: Sintilimab plus gemcitabine and cisplatin was generally safe and well tolerated in the study with a promising efficacy, suggesting that sintilimab may be a new solution for first line treatment of scNSCLC. A multi-center, double blind, randomized Phase III clinical trial with sintilimab is ongoing based on the evidence from current study. Background: Patients (pts) with ROS1+ advanced NSCLC can be effectively treated with ROS1 tyrosine kinase inhibitors (TKIs). However, acquired resistance inevitably develops, resulting in disease relapse. Repotrectinib is a potent next-generation ROS1/TRK/ALK TKI, which inhibits ROS1 with a >90-fold greater potency (IC 50 <0.2 nM) than crizotinib. Preclinical studies demonstrate robust activity of repotrectinib against all known clinical ROS1 resistance mutations, including ROS1 G2032R resistance solvent-front mutation. Method: In this phase I study (NCT03093116), eligible adult pts with TKI-naïve or -pretreated advanced ALK/ROS1/TRK+ solid tumors received repotrectinib. Asymptomatic brain metastases were allowed. Primary objectives were to determine the MTD and RP2D of repotrectinib. Secondary objectives were to assess the safety, pharmacokinetics, and preliminary anti-tumor efficacy. This is a subgroup analysis of the ROS1+ NSCLC pts enrolled in the study. Results: As of July 13, 2018, 30 pts with advanced ROS1+ NSCLC have been treated at 5 dose levels, ranging from 40 to 240 mg/day and 160 mg twice a day; 10 were TKInaïve pts; 20 were TKI-refractory pts; and 16 had baseline CNS metastases. Based on Blinded Independent Central Review (BICR), 27 ROS1+ NSCLC pts were evaluable (10 TKI-naïve and 17 TKI-pretreated) and anti-tumor activity was observed at all dose levels. The confirmed objective response rate (ORR) was 80% in TKI-naïve pts, 18% in all TKI-pretreated pts, and 23% in patients with 1 prior TKI treatment. The intracranial confirmed ORR was 100% and 25% for TKI-naïve and TKI-pretreated pts, respectively. Tumor regressions were observed in 4 crizotinib-pretreated patients with a ROS1 G2032R solvent front resistance mutation, with 1 confirmed PR having a duration of response of 7.4 months dosed at 160 mg QD. A total of 72 pts has been treated in the ongoing TRIDENT-1 Phase 1 study and comprise the safety analysis group. Common (>10% of pts) treatment-related AEs included dizziness (50%), dysgeusia (46%), paresthesia (29%), constipation (19%), fatigue (18%), anemia (12.5 %) and nausea (11%). 4 DLTs were observed including 2 Grade 3 and 1 Grade 2 dizziness (at doses 240 mg QD and above) and 1 Grade 3 case of dyspnea and hypoxia. The MTD has not yet been reached. Conclusion: Repotrectinib is well tolerated and demonstrates promising activity in pts with advanced ROS1+ NSCLC, including those who failed prior TKI(s) or have tumors with solvent-front ROS1 resistance mutations. These phase 1 data warrant further clinical testing of repotrectinib in ROS1+ NSCLC. Keywords: G2032R, Mutation, resistance, ROS1
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